Collectively, clinical evidence in SLE indicates that CD19-directed CAR-T cells can result in the reduction in the SLEDAI scores, resolution of proteinuria, normalization of complement levels, and, in some cases, achievement of complete remission. Here, CD19 is linked to systemic lupus erythematosus.